Targeted cell delivery of mesenchymal stem cell therapy for cardiovascular disease applications: a review of preclinical advancements

Frontiers in Cardiovascular Medicine

Cardiovascular Medicine

Yulexi Y. Ortiz¹  Carlos Theodore Huerta¹  Francesca A. Voza¹  Omaida C. Velazquez²  Zhao-Jun Liu² 

[1] DeWitt Daughtry Family Department of Surgery, University of Miami Miller School of Medicine, Miami, FL, United States;DeWitt Daughtry Family Department of Surgery, University of Miami Miller School of Medicine, Miami, FL, United States;Vascular Biology Institute, University of Miami Miller School of Medicine, Miami, FL, United States;Department of Biochemistry & Molecular Biology, University of Miami Miller School of Medicine, Miami, FL, United States;

关键词: targeted cell delivery;    mesenchymal stem cell;    stem cell therapy;    cell-based therapy;    cardiovascular disease;    chronic limb-threatening ischemia;    myocardial infarction;   

DOI  :  10.3389/fcvm.2023.1236345

 received in 2023-06-07, accepted in 2023-07-25,  发布年份 2023

来源: Frontiers

【 摘 要 】

Cardiovascular diseases (CVD) continue to be the leading cause of morbidity and mortality globally and claim the lives of over 17 million people annually. Current management of CVD includes risk factor modification and preventative strategies including dietary and lifestyle changes, smoking cessation, medical management of hypertension and cholesterol lipid levels, and even surgical revascularization procedures if needed. Although these strategies have shown therapeutic efficacy in reducing major adverse cardiovascular events such as heart attack, stroke, symptoms of chronic limb-threatening ischemia (CLTI), and major limb amputation significant compliance by patients and caregivers is required and off-target effects from systemic medications can still result in organ dysfunction. Stem cell therapy holds major potential for CVD applications but is limited by the low quantities of cells that are able to traffic to and engraft at diseased tissue sites. New preclinical investigations have been undertaken to modify mesenchymal stem cells (MSCs) to achieve targeted cell delivery after systemic administration. Although previous reviews have focused broadly on the modification of MSCs for numerous local or intracoronary administration strategies, here we review recent preclinical advances related to overcoming challenges imposed by the high velocity and dynamic flow of the circulatory system to specifically deliver MSCs to ischemic cardiac and peripheral tissue sites. Many of these technologies can also be applied for the targeted delivery of other types of therapeutic cells for treating various diseases.

【 授权许可】

Unknown   
© 2023 Huerta, Voza, Ortiz, Liu and Velazquez.